Two existing drugs prevent COVID-19 in human cells: Study
PTI, Aug 18, 2020, 1:37 PM IST
Boston: Two existing drugs inhibit SARS-CoV-2, the virus that causes COVID-19, from infecting human cells in the lab, a study has found.
According to the study, published in the journal PNAS, both drugs, vacuolin-1, and apilimod, originally developed years ago, target a large enzyme called PIKfyve kinase.
“Before this study, little was known about this enzyme”s role in COVID-19 infection,” the researchers said.
“The work, which will need to be replicated in human trials, suggests a potential new target for COVID-19 therapies,” they said.
“Our findings show that targeting this kinase through a small-molecule antiviral against SARS-CoV-2 may be an effective strategy to lessen the progression or seriousness of COVID-19,” said study co-senior author Tomas Kirchhausen, a professor at the Harvard Medical School (HMS) in the US.
Kirchhausen said that he discovered vacuolin-1 16 years ago, while apilimod was developed by a company called LAM Therapeutics.
Kirchhausen performed cell biology studies with the SARS-CoV-2 virus in the lab of Sean Whelan, who had been part of the Center for Excellence team at HMS.
“Within a week, we knew apilimod worked extremely well in preventing SARS-CoV-2 infection in human cells in the lab,” said Kirchhausen, who initially published this discovery on the bioRxiv pre-print website in April 2020.
That pre-print also included a review of apilimod”s effectiveness against Ebola and SARS-CoV-2.
“We found that like apilimod, vacuolin-1 is a very strong inhibitor for viral infection in the lab,” said Kirchhausen.
The HMS researchers noted that an unrelated group has published a paper in the journal Nature, showing that, in a screen of 12,000 clinical-stage or FDA-approved small molecules, apilimod was one of the best drugs for inhibiting SARS-CoV-2 virus replication.
Udayavani is now on Telegram. Click here to join our channel and stay updated with the latest news.
DK receives 3,400 doses of Covishield vaccine; People waiting for second dose to be prioritized
70 per cent Covishield stock for vaccination of 45-plus age- group due for 2nd dose in K’taka
‘Will demolish the virus’: Kangana Ranaut tests positive for Covid
Related Articles More
NASA Mars helicopter heard humming through planet’s thin air
Paytm launches COVID-19 vaccine finder tool
Some Twitter users can now leave a tip for tweeters
Wozart Launches Affordable Smart Home Devices to Help Save Energy in Indian Homes
Total collapse of governance: Moily slams Centre over COVID pandemic handling
Mangaluru: Lightning strike damages main tower of Church in Fajir
Sena slams Modi govt for Central Vista project amid pandemic
Govt revises COVID-19 test rules for people arriving in State
Wearing gloves or washing hands frequently? Check what WHO suggests